Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Free Cash Flow (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Free Cash Flow data on record, last reported at -$30.6 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 43.53% year-over-year to -$30.6 million; the TTM value through Sep 2025 reached -$109.6 million, down 74.92%, while the annual FY2024 figure was -$78.3 million, 111.75% down from the prior year.
  • Free Cash Flow reached -$30.6 million in Q3 2025 per DNTH's latest filing, down from -$23.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $16.4 million in Q3 2022 and bottomed at -$30.6 million in Q3 2025.
  • Average Free Cash Flow over 4 years is -$15.1 million, with a median of -$15.0 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: surged 72.02% in 2023, then crashed 206.08% in 2024.
  • A 4-year view of Free Cash Flow shows it stood at -$8.9 million in 2022, then plummeted by 33.6% to -$11.9 million in 2023, then crashed by 131.58% to -$27.5 million in 2024, then dropped by 11.23% to -$30.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$30.6 million in Q3 2025, -$23.9 million in Q2 2025, and -$27.7 million in Q1 2025.